<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="471">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02639091</url>
  </required_header>
  <id_info>
    <org_study_id>17631</org_study_id>
    <nct_id>NCT02639091</nct_id>
  </id_info>
  <brief_title>Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors</brief_title>
  <official_title>An Open Label Phase Ib Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Maximum Tolerated Dose of Anetumab Ravtansine in Combination With Pemetrexed 500 mg/m2 and Cisplatin 75 mg/m2 in Subjects With Mesothelin-expressing Predominantly Epithelial Mesothelioma or Nonsquamous Non-small-cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine the safety, tolerability and maximum tolerated dose of anetumab ravtansine (BAY
      94-9343) in combination with pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 in subjects with
      mesothelin-expressing predominantly epithelial mesothelioma or nonsquamous non-small-cell
      lung cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>MTD is defined as the highest dose of oral anetumab ravtansine (BAY 94-9343) administered in combination with IV pemetrexed and cisplatin that can be given such that not more than 1 of 6 subjects at a given dose level experience a DLT (dose-limiting toxicity).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with adverse events and serious adverse events as a measure of safety and tolerability</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of anetumab ravtansine (BAY 94-9343), pemetrexed and cisplatin</measure>
    <time_frame>- BAY 94-9343: C1D1,D2,D3,D8,D15, C2D1, C3D1,D2,D3,D8,D15, C4D1, C6D1 and subsequent cycles every 3rd cycle up to 2 years or until discontinuation of study treatment, whichever comes first - Pemetrexed: C1D1, D2, D3 - Cisplatin: C1D1, D2, D3</time_frame>
    <safety_issue>No</safety_issue>
    <description>C (treatment cycle), D (day); Each cycle is defined as a period of 21 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response evaluation following mRECIST criteria to determine the number of patients with CR, PR, SD or PD</measure>
    <time_frame>Baseline, every 8 weeks up to cycle 12; then every 12 weeks from cycle 13 up to 2 years, or until discontinuation of study treatment, whichever comes first</time_frame>
    <safety_issue>No</safety_issue>
    <description>CR (complete response); PR (partial response); SD (stable disease); PD (progressive disease); Each cycle is defined as a period of 21 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with a positive titer of anti-drug antibodies</measure>
    <time_frame>Day1 of C1, C3, C6 and subsequent cycles every 3rd cycle up to 2 years or until discontinuation of study treatment, whichever comes first</time_frame>
    <safety_issue>No</safety_issue>
    <description>Each cycle is defined as a period of 21 days</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Medical Oncology</condition>
  <arm_group>
    <arm_group_label>BAY 94-9343 + Pemetrexed + Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigating the combination of anetumab ravtansine (BAY 94-9343) with Pemetrexed (500 mg/m2) and Cisplatin (75 mg/m2) in a dose escalation/de-escalation cohort (Part1) and an MTD expansion cohort (Part 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY 94-9343</intervention_name>
    <description>In Part 1 of the study, anetumab ravtansine (BAY 94-9343) will be administered by 1-hour IV infusion with a starting dose of 5.5mg/kg(BW) on Day 1 of every treatment cycle (Q3W).
In Part 2 of the study, anetumab ravtansine (BAY 94-9343) will be administered on Day 2 of Cycle 1 and then on Day 1 of Cycle 2 and all subsequent cycles (Q3W)</description>
    <arm_group_label>BAY 94-9343 + Pemetrexed + Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Administered at the dose of 500 mg/m2 body surface area (BSA) by 10-minute IV infusion on Day 1 of every treatment cycle (Q3W) in both parts of the study</description>
    <arm_group_label>BAY 94-9343 + Pemetrexed + Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Administered at the dose of 75 mg/m2 (BSA) by 2-hour IV infusion on Day 1 of every treatment cycle (Q3W) in both parts of the study</description>
    <arm_group_label>BAY 94-9343 + Pemetrexed + Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects may be male or female, and must be aged =/&gt;18 years on the date of signing
             the informed consent form.

          -  Subjects must have histologically confirmed, unresectable, locally advanced or
             metastatic pleural or peritoneal predominantly (&gt;50% of tumor component) epithelial
             mesothelioma or nonsquamous non-small-cell lung cancer (NSCLC). Both
             chemotherapy-naive and previously treated subjects will be eligible; however, newly
             diagnosed NSCLC subjects eligible for FDA-approved therapies should have received the
             same before enrollment (e.g. subjects with epidermal growth factor receptor
             [EGFR]-mutated and anaplastic lymphoma kinase [ALK]-translocated NSCLC should have
             received FDA-approved targeted therapies).

          -  Subjects must provide sample of archival Tumor tissue (tissue block preferred, at
             least 5 formalinfixated, paraffin-embedded [FFPE] slides acceptable) collected any
             time before the General screening.

          -  Subjects must have positive mesothelin expression in the archival tumor tissue,
             defined as the mesothelin membrane intensity score of 1+, 2+ or 3+ (on the 0-3 scale)
             expressed on the membrane of ≥5% of tumor cells.

          -  Subjects must have at least 1 measurable or evaluable tumor lesion according to
             RECIST 1.1 (for nonsquamous NSCLC) or mRECIST (for epithelial pleural mesothelioma).
             Subjects with resected primary tumors who have documented metastases are eligible.

          -  Subjects must have a life expectancy of at least 12 weeks.

          -  Subjects must have ECOG (Eastern Cooperative Oncology Group performance Status of 0
             or 1

          -  Subjects must have adequate bone marrow, liver, kidney, and coagulation functions.

        Exclusion Criteria:

          -  Subjects who have a previous or concurrent cancer that is distinct in primary site or
             histology from the cancer being evaluated in this study, or any previous cancer
             curatively treated &lt;3 years before the start of study Treatment.

          -  Subjects who have a history or current evidence of bleeding disorder, i.e. any
             hemorrhage / bleeding event of CTCAE (Common Terminology Criteria for Adverse Events)
             Grade ≥2 within 4 weeks before the start of study Treatment.

          -  Subjects who have new or progressive brain or meningeal or spinal metastases.

          -  Subjects who have a history or current evidence of uncontrolled cardiovascular
             disease i.e. NYHA (New York Heart Association) Class III or IV.

          -  Subjects who have a history or current evidence of uncontrolled hypertension defined
             as systolic blood pressure &gt;150 mmHg or diastolic blood pressure &gt;95 mmHg at
             screening despite optimal medical management.

          -  Subjects who have a history or current evidence of malignant biliary obstruction
             requiring biliary stent.

          -  Subjects who have had solid organ or bone marrow Transplantation.

          -  Subjects who have a history of hypersensitivity to any of the study drugs or their
             excipients, or a history of severe hypersensitivity to any other Antigen.

          -  Subjects who have a history of human immunodeficiency virus (HIV) infection or
             subjects who have an active hepatitis B virus (HBV) or hepatitis C virus (HCV)
             infection requiring treatment.

          -  Subjects who have an active clinically serious infection of CTCAE Grade ≥2 or
             non-healing wound unrelated to the primary Tumor.

          -  Subjects who have received systemic cancer therapy, radiotherapy, granulocyte
             colonystimulating factors, (G-CSF) or granulocyte macrophage-stimulating factors
             (GM-CSF), erythropoietin-stimulating agents, investigational drug treatment outside
             of this study within 4 weeks before the start of study treatment, drugs with known
             renal toxicity and strong cytochrome P450 3A4 (CYP3A4) inhibitors or strong CYP3A4
             inducers.

          -  Subjects who have started oral or parenteral anticoagulation therapy within 2 weeks
             before the start of anetumab ravtansine until end of treatment visit.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <email>clinical-trials-contact@bayer.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 25, 2016</lastchanged_date>
  <firstreceived_date>November 30, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Solid tumors</keyword>
  <keyword>Mesothelioma</keyword>
  <keyword>Lung cancer</keyword>
  <keyword>Pemetrexed</keyword>
  <keyword>Cisplatin</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Immunoconjugates</mesh_term>
    <mesh_term>Maytansine</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
